Mylan Specialty, which markets and distributes the EpiPen® brand of epinephrine auto-injector, has issued a press release confirming they have adequate supply to meet the demand of consumers affected by the recent Auvi-Q® recall.
Says Heather Bresch, CEO of Mylan:
We are confident that the widespread familiarity with EpiPen® Auto-Injector established over more than 25 years, coupled with our robust training resources, will provide access and support for those impacted by the Auvi-Q® recall. Anaphylaxis is unpredictable, and should an emergency occur, patient preparedness and immediate access to reliable treatment is critical. Mylan continues to be committed to help ensure access to epinephrine, the first-line treatment for anaphylaxis, and is working to provide a seamless transition for patients and their caregivers who may now be prescribed EpiPen® Auto-Injector.
You can see Mylan’s entire press release by clicking here. We suggest you also read our article: Replacing Your Auvi-Qs: Auto-Injector Options and Offers.
Print or share this article
